Ciudadela

This trial studies participants with multiple myeloma, focusing on those who have received prior therapies. The research is divided into three parts: Part 1 evaluates the safety and clinical effects of increasing doses of unconjugated belantamab antibody in patients with refractory multiple myeloma who have had at least three prior treatments. Part 2 examines safety and clinical effects of different dose combinations of belantamab mafodotin with unconjugated belantamab antibody in similar patients. Part 3 assesses the clinical activity of a selected dose of unconjugated belantamab antibody alone or combined with belantamab mafodotin and a standard treatment backbone, in patients who have received at least one prior therapy including lenalidomide. Participants receive treatments including unconjugated belantamab antibody alone, belantamab mafodotin alone, their combination as separate drugs, or unconjugated belantamab antibody and belantamab mafodotin combined with pomalidomide and dexamethasone. Each part has its specific dosing and combination schedules. The study includes a dose escalation phase and expansion phases to assess treatments' effects in different combinations. Participants are monitored for up to 52 months for safety, side effects, and clinical response. Assessments include tracking adverse events, laboratory and vital sign changes, eye-related effects measured by the Keratopathy Visual Acuity scale, and response rates such as overall and very good partial responses. Participants undergo regular evaluations including lab tests and clinical exams to ensure safety and measure treatment outcomes throughout the study duration.

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.